从China供应商批量进口3'-Hydroxyacetophenone, Cas.No.121-71-1

3'-Hydroxyacetophenone (CAS 121-71-1, molecular weight 136.1, formula C8H8O2) functions as a versatile aromatic ketone intermediate with broad utility across pharmaceutical synthesis, cosmetic formulation, and specialty chemical manufacturing. Beijing Thtd Pharmaceutical Technology Co., Ltd. offers this material from its Beijing location with stated purity exceeding 99%, though the precise analytical methodology underpinning this figure requires direct confirmation. The compound's structural features, a phenolic hydroxyl para to the ketone carbonyl on the acetophenone scaffold, enable participation in condensation, reduction, and substitution chemistries that form the backbone of numerous synthetic routes to bioactive molecules and functional materials.

Industrial production of 3'-hydroxyacetophenone typically proceeds through acylation of m-hydroxybenzoic acid derivatives or via rearrangement reactions, with commercial grades differentiated by impurity profiles rather than gross composition alone. Standard quality parameters for this compound include chromatographic purity, melting point range, and absence of isomeric contaminants, particularly the 2'- and 4'-hydroxy positional isomers that may arise from imprecise synthetic control. The material's phenolic character necessitates protection from atmospheric oxidation during storage, with typical industry practice involving nitrogen-flushed containers and inclusion of chelating agents to sequester trace metal catalysts. Solubility characteristics, moderate in aqueous systems and good in polar aprotic solvents, govern its handling in batch reactor environments and its incorporation into aqueous-based cosmetic preparations.

Downstream applications span the synthesis of H1-antihistamines where the 3'-hydroxyacetophenone skeleton serves as a precursor to ethanolamine derivatives, through to fragrance compounding where it contributes to vanillic and coumarinic odor profiles. Agrochemical researchers employ it in the construction of strobilurin-type fungicides, while polymer chemists explore its use in thermosetting resins. The buyer base includes custom synthesis houses, generic API manufacturers, and multinational flavour and fragrance firms. Beijing Thtd Pharmaceutical Technology Co., Ltd. does not specify its minimum order quantity, lead time, or packaging details in the listing data, so importers must negotiate these commercial terms directly. The supplier's zero percent response rate on this platform indicates that direct outreach through alternative channels may prove more effective than relying on platform-mediated enquiry alone.

Beijing Thtd Pharmaceutical Technology Co., Ltd. maintains its registered address at No.21 Tianhua Street, Zhongguancun Science Park, Daxing Bio-Medical Industry Park, Daxing 102600, Beijing, China, a location within a government-designated zone intended to cluster life science and advanced materials enterprises. The supplier's imported tier classification indicates that its commercial model may involve the importation and redistribution of chemical products alongside any domestic manufacturing operations. Its harbor trust tier and zero percent response rate, combined with zero average response hours, reveal a profile with minimal demonstrated transactional history through the platform channel, which prospective buyers should weigh appropriately in their risk assessment.

The supplier profile omits founding date, ownership structure, number of employees, annual turnover, manufacturing facility certifications, and named customers or reference projects. These absences are material information gaps that direct due diligence must address. What can be inferred from the address is proximity to academic institutions and research hospitals that may facilitate analytical testing access or collaborative development, though this speculation requires verification. For buyers requiring GMP-compliant materials, DMF-supported supply, or audit trail documentation, the onus rests entirely on direct inquiry to Beijing Thtd Pharmaceutical Technology Co., Ltd. to produce evidence of capability, as the platform listing does not substantiate such qualifications.